Anxiety, Depression & Mood FAQs

Anxiety, Depression & Mood FAQs

The 50 most-searched questions on anxiety, depression, mood disorders, panic, bipolar, postpartum depression, mood swings, and treatment options — answered with peer-reviewed evidence from APA, NIMH, JAMA Psychiatry, The Lancet Psychiatry, Cochrane reviews, and World Psychiatry. Each answer cites numbered references that match the full reference list at the bottom of the page.

Anxiety — what it is, symptoms, and causes

1. What is anxiety and how is it different from normal worry?

Anxiety is the body and mind’s natural response to perceived threat — a future-oriented state involving apprehension, physiological arousal, and avoidance preparation [1]. Normal worry is brief, proportionate to a real stressor, and resolves when the situation does. An anxiety disorder is diagnosed when worry or fear is excessive, persistent (typically ≥6 months for generalized anxiety disorder), out of proportion to actual risk, hard to control, and significantly impairs daily functioning [2]. Lifetime prevalence of any anxiety disorder is approximately 33.7% globally, making it the most common mental health condition [3].

2. What are the symptoms of an anxiety disorder?

Core symptoms include excessive worry that is difficult to control, restlessness or feeling on edge, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance — at least three of these are required for generalized anxiety disorder [2]. Physical symptoms commonly include rapid heartbeat, sweating, trembling, shortness of breath, dizziness, nausea, and gastrointestinal upset, driven by sympathetic nervous system activation [4]. Cognitive symptoms include catastrophic thinking, anticipatory dread, and difficulty tolerating uncertainty [5].

3. What does a panic attack feel like and how long does it last?

A panic attack is an abrupt surge of intense fear or discomfort that peaks within about 10 minutes and typically lasts 20–30 minutes total, with at least four of the following: pounding heart, sweating, trembling, shortness of breath, choking sensation, chest pain, nausea, dizziness, chills or hot flushes, numbness/tingling, derealization, fear of losing control, or fear of dying [2,6]. Although extremely distressing, panic attacks are not physically dangerous and do not cause heart attacks in healthy individuals [7]. Approximately 11% of adults experience a panic attack each year [8].

4. What is the difference between a panic attack and an anxiety attack?

“Panic attack” is a clinical DSM-5 term with specific diagnostic criteria: an abrupt surge of intense fear that peaks within minutes and includes at least four physiological symptoms [2]. “Anxiety attack” is a colloquial term not in the DSM — it usually describes a more gradual buildup of worry, tension, and physical symptoms in response to an identifiable stressor, typically lasting longer at lower intensity [6]. Panic attacks are typically unexpected and decoupled from triggers, whereas anxiety symptoms tend to be tied to specific stressors and accumulate over time [9].

5. What causes anxiety disorders?

Anxiety disorders arise from a combination of genetic vulnerability (heritability ~30–50%), neurobiological factors (heightened amygdala reactivity, reduced prefrontal cortex regulation, dysregulation of GABA, serotonin, and norepinephrine systems), early adversity and trauma, chronic stress, learned avoidance behaviors, and personality traits such as neuroticism and behavioral inhibition [10,11]. Medical conditions (hyperthyroidism, cardiac arrhythmias), substance use (caffeine, stimulants, alcohol withdrawal), and certain medications can also trigger or worsen anxiety [12].

6. Is anxiety genetic or hereditary?

Yes, in part. Twin studies estimate the heritability of anxiety disorders at approximately 30–50%, meaning genes account for about one-third to one-half of the risk; the remainder reflects environmental factors such as adverse childhood experiences, trauma, parenting style, and life stressors [13,14]. Genome-wide association studies have identified multiple genetic loci linked to anxiety traits, but no single “anxiety gene” exists — risk is polygenic and interacts strongly with environment [15].

7. What are the different types of anxiety disorders?

The DSM-5 recognizes several anxiety disorders [2]: generalized anxiety disorder (GAD) — chronic excessive worry across multiple domains; panic disorder — recurrent unexpected panic attacks plus persistent concern about future attacks; social anxiety disorder — intense fear of scrutiny or negative evaluation in social situations; specific phobias — marked fear of specific objects or situations (heights, animals, blood, flying); agoraphobia — fear of situations where escape might be difficult; and separation anxiety disorder. OCD and PTSD were reclassified in DSM-5 into separate categories but share many features with anxiety disorders [16].

8. What is the difference between stress and anxiety?

Stress is a response to an identifiable external demand or threat and typically resolves when the stressor is removed [17]. Anxiety persists even in the absence of a clear external trigger, is future-oriented, and often involves anticipatory worry about events that may never occur [1]. Acute stress can be adaptive and improve performance, while sustained stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis and increases risk for anxiety and depressive disorders [18].

9. Can anxiety cause physical symptoms?

Yes. Anxiety triggers sympathetic nervous system activation, producing chest tightness or pain, palpitations, shortness of breath, dizziness, nausea, diarrhea, muscle tension, headaches, sweating, trembling, and tingling in the extremities [4,19]. Chronic anxiety is also associated with increased risk of cardiovascular disease, irritable bowel syndrome, tension headaches, and immune dysregulation [20]. Because anxiety can mimic cardiac and respiratory conditions, new or severe physical symptoms should always be evaluated medically before being attributed to anxiety [7].

10. Why do I feel anxious for no reason?

“Anxiety from nowhere” usually has identifiable causes that are not consciously recognized: subclinical caffeine or stimulant effects, poor or fragmented sleep, blood sugar fluctuations, hormonal shifts (premenstrual, perimenopausal, thyroid), withdrawal from alcohol or sedatives, low-grade chronic stress, unresolved trauma, or genetic predisposition expressed as baseline hyperarousal [12,21]. Interoceptive sensitivity — heightened awareness of normal bodily sensations — can also be misinterpreted as threat, generating anxiety in the absence of an external trigger [22].

Anxiety — treatment, coping, and daily management

11. How do I stop a panic attack quickly?

Evidence-based techniques include slow diaphragmatic breathing (inhale 4 seconds, exhale 6–8 seconds) to activate the parasympathetic nervous system [23]; the 5-4-3-2-1 grounding exercise (name 5 things you see, 4 you feel, 3 you hear, 2 you smell, 1 you taste) to redirect attention from internal sensations [24]; cold-water exposure (splashing the face or holding a cold object) which triggers the mammalian dive reflex and slows heart rate [25]; and accepting the attack rather than fighting it — research shows resistance prolongs panic, while acceptance shortens it [26]. Reminding yourself that panic peaks within ~10 minutes and is not dangerous reduces secondary fear [7].

12. What are the best treatments for anxiety?

The two first-line evidence-based treatments are cognitive-behavioral therapy (CBT) — including exposure therapy for phobias, panic, and social anxiety — and SSRIs/SNRIs [27,28]. Meta-analyses show CBT produces large effect sizes (Cohen’s d ≈ 0.80) and gains are durable at long-term follow-up, often outperforming medication on relapse prevention [29]. SSRIs (escitalopram, sertraline, paroxetine) and SNRIs (venlafaxine, duloxetine) are first-line pharmacotherapy [28]. Combining CBT with medication is often more effective than either alone for moderate-to-severe cases [30].

13. Do anxiety medications work and what are the side effects?

SSRIs and SNRIs are first-line and produce response in approximately 50–65% of patients within 4–8 weeks; full benefit can take 12 weeks [28,31]. Common side effects include nausea, sexual dysfunction, sleep changes, sweating, and weight change; most diminish within 2–4 weeks [32]. Benzodiazepines (lorazepam, clonazepam) work within 30 minutes for acute anxiety but carry significant risks of tolerance, dependence, and cognitive impairment, and are recommended only for short-term use (≤2–4 weeks) or specific situations [33]. Buspirone and pregabalin are non-addictive alternatives for generalized anxiety [34].

14. Can anxiety be cured or does it come back?

Anxiety disorders are highly treatable but typically managed rather than “cured.” Approximately 60–80% of patients achieve significant improvement with evidence-based treatment, and many achieve remission [35]. However, anxiety has a chronic-recurrent course in many people, with relapse rates of 20–50% over 5–10 years, particularly after medication discontinuation [36]. CBT is associated with lower relapse rates than medication, likely because skills learned in therapy persist beyond treatment [29].

15. How can I reduce anxiety naturally without medication?

Evidence-based non-pharmacological strategies include regular aerobic exercise (≥150 min/week — comparable to medication for mild-to-moderate anxiety) [37], mindfulness-based stress reduction (MBSR) [38], cognitive-behavioral self-help and digital CBT programs [39], yoga and structured breathing practices [40], adequate sleep (7–9 hours) [41], limiting caffeine and alcohol [42], and social connection [43]. These approaches are most effective when combined and are recommended as first-line for mild anxiety per international guidelines [27].

16. Does exercise help anxiety?

Yes — robustly. Meta-analyses of randomized trials show aerobic and resistance exercise produce moderate-to-large reductions in anxiety symptoms, with effect sizes (Cohen’s d ≈ 0.55–0.85) comparable to first-line medications and CBT for mild-to-moderate anxiety [37,44]. Mechanisms include reduced HPA-axis reactivity, increased GABA and serotonin availability, elevated BDNF (brain-derived neurotrophic factor), and improved sleep [45]. Even single sessions of 20–30 minutes of moderate-intensity exercise produce measurable acute anxiolytic effects [46].

17. How does caffeine, alcohol, or nicotine affect anxiety?

Caffeine antagonizes adenosine receptors and stimulates the sympathetic nervous system; doses ≥200 mg can induce panic attacks in susceptible individuals, and >400 mg/day increases generalized anxiety [42,47]. Alcohol initially reduces anxiety via GABA enhancement but causes rebound anxiety during withdrawal (often 6–24 hours after last drink); chronic use worsens anxiety disorders and reduces treatment response [48]. Nicotine produces brief calming via acetylcholine receptors but cumulative use elevates baseline anxiety; quitting is associated with significant long-term anxiety reduction [49].

18. How do breathing exercises and grounding techniques help anxiety?

Slow paced breathing (≤6 breaths per minute) increases vagal tone, activates the parasympathetic nervous system, raises heart rate variability, and reduces amygdala activation, producing measurable reductions in state anxiety within minutes [23,50]. Grounding techniques (5-4-3-2-1, body scan, naming objects) shift attention from internal threat-monitoring to external sensory input, interrupting catastrophic thinking and dampening interoceptive amplification [24,51]. Both techniques are evidence-based components of CBT and trauma-focused therapy [52].

Depression — what it is, symptoms, and causes

19. What is depression and how is it different from sadness?

Sadness is a normal, time-limited emotional response to loss or disappointment that does not significantly impair functioning. Major depressive disorder (MDD) is a clinical syndrome lasting at least two weeks with five or more of: depressed mood, loss of interest or pleasure (anhedonia), significant weight or appetite change, sleep disturbance, psychomotor agitation or slowing, fatigue, feelings of worthlessness or excessive guilt, impaired concentration, and recurrent thoughts of death or suicide [2,53]. Depression involves persistent biological and cognitive changes — including HPA-axis dysregulation, reduced hippocampal volume, and negatively biased information processing — that distinguish it from ordinary sadness [54].

20. What are the symptoms of clinical depression (MDD)?

DSM-5 requires ≥5 symptoms for ≥2 weeks, including at least one of depressed mood or anhedonia [2]: persistent low mood; loss of interest or pleasure; significant weight loss or gain (>5%) or appetite change; insomnia or hypersomnia; psychomotor agitation or retardation observable to others; fatigue or loss of energy; feelings of worthlessness or excessive guilt; impaired concentration or indecisiveness; and recurrent thoughts of death or suicide. Symptoms must cause significant distress or functional impairment and not be better explained by substance use or another medical condition [53].

21. What causes depression?

Depression has a multifactorial etiology: genetic (heritability ~37%) [55]; neurobiological — dysregulation of serotonin, norepinephrine, and dopamine systems; HPA-axis hyperactivity; neuroinflammation; reduced hippocampal and prefrontal volumes [54,56]; psychological — negative cognitive schemas, rumination, learned helplessness [57]; environmental — childhood adversity, trauma, chronic stress, loss, social isolation, financial strain [58]; and medical — hypothyroidism, vitamin D and B12 deficiency, certain medications, chronic illness, and substance use [59]. The most accepted framework is the biopsychosocial model.

22. Is depression genetic?

Partly. Twin studies estimate heritability of major depression at approximately 37% [55]. Having a first-degree relative with depression increases personal risk roughly 2–3 fold [60]. However, no single “depression gene” exists — depression is highly polygenic, with hundreds of small-effect genetic variants identified by genome-wide association studies, and gene-environment interactions (especially with childhood adversity) are central to risk [15,61].

23. What is the difference between major depression, persistent depressive disorder, and seasonal affective disorder?

Major depressive disorder (MDD) — discrete episodes of ≥2 weeks of severe symptoms; episodes can be single or recurrent [2]. Persistent depressive disorder (dysthymia) — chronic, lower-intensity depressed mood lasting ≥2 years (≥1 year in youth) with at least two associated symptoms [2,62]. Seasonal affective disorder (SAD) — a specifier of recurrent MDD or bipolar disorder with episodes occurring in a seasonal pattern (typically fall/winter) and remitting in spring/summer; linked to reduced daylight and circadian disruption [63]. SAD responds well to bright-light therapy (10,000 lux for 30 minutes each morning) [64].

24. Can depression cause physical symptoms?

Yes. Common physical manifestations include persistent fatigue, unexplained aches and pains, headaches, gastrointestinal symptoms, sleep disturbance, appetite and weight changes, psychomotor slowing, and reduced libido [65]. Physical symptoms are often the presenting complaint in primary care, and unexplained somatic symptoms are present in up to 76% of depressed patients [66]. Depression also increases inflammation (elevated CRP, IL-6) and is associated with higher rates of cardiovascular disease, diabetes, and chronic pain syndromes [67].

25. What is high-functioning depression?

“High-functioning depression” is a colloquial term — not a formal diagnosis — usually corresponding to persistent depressive disorder (dysthymia) or atypical/mild MDD in individuals who maintain work, school, and relationships despite chronic depressive symptoms [62,68]. People with this presentation often experience persistent low mood, anhedonia, fatigue, low self-esteem, and rumination but are reluctant to seek help because they are “still functioning.” Untreated, it carries elevated risk of progression to major depressive episodes and suicidal ideation, and warrants the same evidence-based treatment as other forms of depression [69].

26. What is postpartum depression and how is it treated?

Postpartum depression (PPD) is major depression with onset during pregnancy or within 4 weeks postpartum (DSM-5 specifier; clinically extended to 12 months); it affects approximately 10–15% of new mothers and a smaller proportion of fathers [70,71]. Symptoms include depressed mood, anhedonia, sleep disruption beyond newborn-related changes, intense guilt or feelings of inadequacy, anxiety, and impaired bonding. Evidence-based treatments include cognitive-behavioral therapy, interpersonal therapy, SSRIs (sertraline is first-line during breastfeeding), and brexanolone or zuranolone (FDA-approved neurosteroids for PPD) [72,73]. Untreated PPD adversely affects maternal, infant, and family outcomes; early identification and treatment are critical.

27. How do I know if I’m depressed or just sad?

Sadness is typically time-limited (hours to a few days), tied to a clear trigger, and does not impair core functioning. Depression involves persistent (≥2 weeks) low mood or loss of interest in nearly all activities, accompanied by changes in sleep, appetite, energy, concentration, self-worth, or thoughts of death [2]. Validated self-report tools such as the PHQ-9 (Patient Health Questionnaire-9) classify scores: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe; scores ≥10 warrant clinical evaluation [74]. If symptoms persist >2 weeks or include hopelessness or suicidal thoughts, professional assessment is recommended.

28. Why do I feel depressed for no reason?

Depression often appears without an obvious external trigger because risk factors are biological, cumulative, or operate outside conscious awareness: genetic predisposition; chronic low-grade stress; circadian and sleep disruption; vitamin D, B12, or iron deficiency; thyroid dysfunction; hormonal fluctuations (premenstrual, postpartum, perimenopausal); chronic inflammation; medication side effects (corticosteroids, beta-blockers, hormonal contraceptives); seasonal light reduction; and unresolved early-life adversity [55,58,59,75]. Endogenous depression — depression with no identifiable trigger — is recognized in clinical practice and responds to the same evidence-based treatments as reactive depression [76].

Depression — treatment and recovery

29. What are the most effective treatments for depression?

First-line evidence-based treatments are psychotherapy (CBT, behavioral activation, interpersonal therapy, problem-solving therapy) and antidepressants (SSRIs, SNRIs, atypicals such as bupropion and mirtazapine) [77,78]. Network meta-analyses show all major antidepressant classes are more effective than placebo, with response rates of 50–60% [78]. Combined therapy plus medication outperforms either alone for moderate-to-severe depression [79]. For treatment-resistant depression, augmentation strategies, ketamine/esketamine, repetitive transcranial magnetic stimulation (rTMS), and electroconvulsive therapy (ECT) have strong evidence [80,81].

30. How long do antidepressants take to work and how long should you stay on them?

Most patients begin to feel partial improvement within 2–4 weeks, with full benefit typically at 6–12 weeks [82]. International guidelines recommend continuing antidepressants for at least 6–9 months after symptom remission for a first episode; for recurrent depression (≥2 episodes), maintenance treatment of 2 years or longer reduces relapse risk substantially [77,83]. Discontinuation should be gradual (typically over weeks to months) and supervised, as abrupt cessation can cause antidepressant discontinuation syndrome — flu-like symptoms, dizziness, sensory disturbances, mood symptoms — particularly with paroxetine and venlafaxine [84].

31. What are the side effects of antidepressants?

Common SSRI/SNRI side effects include nausea, headache, insomnia or somnolence, sexual dysfunction (30–70%), weight change, sweating, and emotional blunting; most adverse effects are dose-dependent and diminish within 2–4 weeks except sexual dysfunction, which often persists [32,85]. Less common but serious risks include serotonin syndrome (with serotonergic combinations), QT prolongation (citalopram >40 mg), bleeding (with NSAIDs/anticoagulants), hyponatremia (especially in older adults), and increased suicidal ideation in those under 25 during the first weeks of treatment [86]. Bupropion lowers seizure threshold and avoids sexual side effects; mirtazapine is sedating and increases appetite [78].

32. Does therapy work for depression?

Yes. Cognitive-behavioral therapy, behavioral activation, interpersonal therapy, and problem-solving therapy each show response rates of approximately 50–60% in meta-analyses, comparable to antidepressant medication [87,88]. CBT in particular demonstrates lower relapse rates than medication after treatment ends, likely because skills are retained [89]. Therapy plus medication outperforms either alone for moderate-severe depression [79]. Even brief interventions (6–8 sessions) and digital CBT programs produce clinically meaningful improvement in mild-to-moderate depression [90].

33. Can depression be cured or does it always come back?

Many people achieve full remission with treatment, but depression has a recurrent course in approximately 50% of those with a first episode, 70% after a second, and 90% after a third [83,91]. Maintenance therapy — continued medication, booster psychotherapy sessions, mindfulness-based cognitive therapy (MBCT), and lifestyle measures — substantially reduces relapse risk [92]. Identifying and addressing residual symptoms (especially sleep, anhedonia, and rumination) and ongoing stressors is key to long-term recovery [93].

34. What helps depression naturally?

Evidence-based non-pharmacological strategies include regular aerobic exercise (≥150 min/week — comparable to medication for mild-to-moderate depression) [94]; bright-light therapy for SAD and non-seasonal depression [64,95]; sleep regularization (consistent schedule, 7–9 hours, sleep-restriction therapy) [96]; Mediterranean-style diet and omega-3 supplementation in those with deficiency [97,98]; mindfulness-based cognitive therapy [92]; behavioral activation [99]; and social connection and reducing isolation [100]. These approaches are recommended in international guidelines as first-line for mild depression and as adjuncts for moderate-severe cases [77].

35. What treatments exist for treatment-resistant depression?

Treatment-resistant depression (TRD) — typically defined as failure of ≥2 adequate antidepressant trials — is treated with: augmentation with lithium, atypical antipsychotics (aripiprazole, quetiapine), or thyroid hormone [80]; ketamine/esketamine (FDA-approved esketamine nasal spray) which produces rapid (within hours) but transient antidepressant effects via NMDA receptor modulation [81]; repetitive transcranial magnetic stimulation (rTMS) — non-invasive, FDA-cleared, response rates ~30–60% [101]; electroconvulsive therapy (ECT) — most effective treatment for severe TRD with response rates 60–80% [102]; and emerging treatments including psilocybin-assisted therapy (in clinical trials) and deep brain stimulation [103].

Mood swings, bipolar disorder, and other mood conditions

36. What causes sudden mood swings?

Common causes of acute mood swings include sleep deprivation, blood sugar fluctuations, hormonal shifts (premenstrual, postpartum, perimenopause, thyroid disorders), substance use or withdrawal (alcohol, caffeine, cannabis, stimulants), medication side effects (corticosteroids, hormonal contraceptives, levothyroxine), chronic stress, and unrecognized mental health conditions including bipolar disorder, borderline personality disorder, ADHD, and premenstrual dysphoric disorder (PMDD) [104,105]. Frequent or severe mood swings — especially episodes lasting days with significant functional impact — warrant clinical assessment.

37. Are mood swings a sign of bipolar disorder?

Not usually. Most everyday mood swings reflect normal emotional reactivity, sleep, stress, or hormonal factors and resolve within hours [104]. Bipolar disorder involves discrete episodes of mania (≥7 days) or hypomania (≥4 days) characterized by elevated or irritable mood, decreased need for sleep, racing thoughts, increased goal-directed activity, grandiosity, and risky behavior — alternating with depressive episodes; brief intraday mood shifts (lasting minutes to hours) are not characteristic of bipolar disorder [2,106]. Rapid mood shifts within a single day are more typical of borderline personality disorder, PMDD, or ADHD-related emotional dysregulation [107].

38. What is the difference between bipolar I, bipolar II, and cyclothymia?

Bipolar I: at least one full manic episode (≥7 days, or any duration if hospitalization is required), often with depressive episodes [2]. Bipolar II: at least one hypomanic episode (≥4 days, less severe than mania, no marked impairment or psychosis) plus at least one major depressive episode; depressive episodes typically dominate the course [108]. Cyclothymia: chronic (≥2 years) fluctuating mood with hypomanic and depressive symptoms that don’t meet full criteria for hypomania or major depression [2]. Lifetime prevalence: bipolar I ~1%, bipolar II ~1.1%, cyclothymia ~0.4–1% [109].

39. What is the difference between mood swings and a mood disorder?

Mood swings are transient emotional fluctuations that respond to context and resolve within hours; they are part of normal emotional life. A mood disorder (major depression, persistent depressive disorder, bipolar disorders, premenstrual dysphoric disorder, disruptive mood dysregulation disorder) involves persistent or recurrent disturbances of mood lasting days to weeks, accompanied by changes in sleep, energy, appetite, concentration, and self-worth, and causing significant distress or functional impairment [2,53]. Frequency, duration, intensity, and impairment distinguish disorders from normal mood variation [110].

40. Can hormones cause mood changes?

Yes. Premenstrual: ~75% of menstruating women experience mild PMS; 3–8% have premenstrual dysphoric disorder (PMDD), a DSM-5 diagnosis with severe mood symptoms in the luteal phase [111]. Postpartum: rapid drops in estrogen and progesterone contribute to “baby blues” (50–80%) and PPD (10–15%) [70]. Perimenopause/menopause: estrogen fluctuations elevate risk of new-onset or recurrent depression by 2–4 fold [112]. Thyroid: hypothyroidism is associated with depression, hyperthyroidism with anxiety and mania [113]. Testosterone: low levels in men contribute to depression and fatigue [114]. Hormonal causes should be screened in any new-onset mood disorder.

41. How do sleep and diet affect mood?

Sleep and mood are bidirectionally linked: chronic sleep restriction (<6 hours) increases risk of depression by ~2-fold and worsens existing mood disorders, while improving sleep quality reliably improves mood [96,115]. Insomnia is both a risk factor for and a residual symptom of depression. Dietary patterns also matter: Mediterranean and traditional diets are associated with 25–35% lower depression risk than Western diets high in refined carbohydrates, processed foods, and saturated fats [97,116]. Specific deficiencies of vitamin D, B12, folate, iron, and omega-3 fatty acids are linked to depressive symptoms and respond to repletion in deficient individuals [98,117].

42. Can vitamin deficiencies cause depression or mood changes?

Yes, in deficient individuals. Vitamin D: deficiency is associated with depression and supplementation modestly improves mood in those with low levels (<50 nmol/L) [117]. Vitamin B12 and folate: deficiencies impair monoamine synthesis and are linked to depression; supplementation helps in deficient patients [118]. Omega-3 (EPA/DHA): meta-analyses show modest antidepressant effects, particularly with EPA-predominant formulations [98]. Iron: deficiency causes fatigue and depressive symptoms, especially in women [119]. Routine supplementation in non-deficient individuals does not prevent or treat depression; testing and targeted repletion are recommended [120].

43. How is bipolar disorder treated?

Bipolar disorder requires lifelong management combining mood stabilizers (lithium — the gold standard, also reduces suicide risk; valproate; lamotrigine — particularly for bipolar depression; carbamazepine), atypical antipsychotics (quetiapine, olanzapine, lurasidone, aripiprazole), and structured psychotherapy (cognitive-behavioral therapy, family-focused therapy, interpersonal and social rhythm therapy) [121,122]. Antidepressant monotherapy is generally avoided in bipolar I due to risk of mania induction. Sleep regularization, mood charting, and substance-use management are essential. ECT is highly effective for severe or treatment-resistant episodes [102].

Co-occurring conditions, suicide safety, and when to seek help

44. Can you have anxiety and depression at the same time?

Yes — comorbidity is the norm, not the exception. Approximately 60% of people with depression also meet criteria for an anxiety disorder, and 50% of those with anxiety disorders develop depression at some point [123,124]. Comorbid anxiety-depression is associated with greater symptom severity, higher suicide risk, longer episodes, and poorer treatment response than either condition alone [125]. SSRIs and SNRIs are first-line for both, and CBT is effective for the combined presentation through transdiagnostic protocols such as the Unified Protocol [126].

45. What is the link between depression and suicide and what are the warning signs?

Depression is the strongest psychiatric risk factor for suicide, accounting for ~50% of suicide deaths [127]. Lifetime risk of suicide in people with major depression is approximately 4%, rising to 15% in severe inpatient cases [128]. Warning signs: talking about wanting to die, hopelessness, feeling trapped or being a burden, increased substance use, withdrawal, dramatic mood changes, giving away possessions, researching means, and prior attempts (the strongest predictor) [129,130]. If you or someone you know is in crisis, contact local emergency services or a suicide hotline immediately — in Canada: 9-8-8 (Suicide Crisis Helpline); in the U.S.: 988; international list at findahelpline.com. Effective interventions include the Safety Planning Intervention, lithium for bipolar, clozapine for schizophrenia, and means restriction [131].

46. When should I see a doctor or therapist for anxiety or depression?

Seek professional evaluation if symptoms persist >2 weeks, interfere with work, school, relationships, or self-care, include hopelessness or suicidal thoughts, involve panic attacks, are accompanied by significant sleep, appetite, or weight changes, or worsen despite self-help [27,77]. Earlier intervention is associated with better outcomes and lower relapse risk. Free PHQ-9 (depression) and GAD-7 (anxiety) screening tools can guide whether to seek care: scores ≥10 on either suggest moderate symptoms warranting clinical assessment [74,132]. Crisis symptoms (suicidal ideation with plan or intent, severe agitation, psychosis) require immediate emergency evaluation.

47. What is the difference between a psychiatrist, psychologist, and therapist?

Psychiatrist: medical doctor (MD or DO) who can diagnose mental disorders and prescribe medication; some also provide psychotherapy [133]. Psychologist: doctoral-level (PhD or PsyD) clinician trained in psychological assessment and evidence-based psychotherapy; cannot prescribe medication in most jurisdictions (exceptions: New Mexico, Louisiana, Illinois, Iowa, Idaho, and a few others). Therapist/counselor: an umbrella term covering licensed clinical social workers (LCSW), licensed mental health counselors (LMHC), licensed marriage and family therapists (LMFT), and registered psychotherapists (RP) — typically master’s-level clinicians who provide psychotherapy [134]. For uncomplicated mild-moderate symptoms, any qualified evidence-based therapist is appropriate; complex, severe, or medication-requiring cases benefit from psychiatrist involvement and a multidisciplinary team.

48. Are anxiety and depression more common in teens, women, or older adults?

Sex differences: women are approximately twice as likely as men to experience depression and most anxiety disorders, beginning in adolescence; this difference reflects hormonal, psychosocial, and reporting factors [135,136]. Age: prevalence of depression and anxiety has increased substantially in adolescents and young adults over the past decade; rates of major depression in teens rose ~60% from 2007–2019 [137]. Older adults: depression in late life is common but underdiagnosed, often presenting with cognitive complaints, somatic symptoms, and anhedonia rather than sadness [138]. Suicide rates are highest among older men, particularly those who are widowed, isolated, or chronically ill [139].

49. Can social media, screen time, or loneliness cause anxiety and depression?

Heavy social media use (>3 hours/day) is associated with increased risk of depression and anxiety in adolescents, with effect sizes that are small-to-moderate but consistent across studies; mechanisms include social comparison, sleep displacement, cyberbullying, and reduced in-person interaction [140,141]. Causality is debated and likely bidirectional, with vulnerable individuals more susceptible. Loneliness independently predicts depression, anxiety, and increased mortality, with effect sizes comparable to smoking [142,143]. Reducing problematic social media use, regular sleep, and structured social connection are evidence-based protective factors [144].

50. Does neurofeedback, mindfulness, or meditation help anxiety, depression, or mood?

Mindfulness-based interventions (MBSR, MBCT) show moderate-to-large effects on anxiety and depression in meta-analyses, with MBCT specifically reducing depression relapse by ~30% and matching maintenance antidepressants for relapse prevention [145,146]. Meditation: regular practice produces measurable changes in default-mode network activity, amygdala reactivity, and prefrontal regulation [147]. Neurofeedback (EEG biofeedback): meta-analyses support efficacy for ADHD, PTSD, and anxiety symptoms; evidence in major depression is growing, with frontal alpha asymmetry and infra-low frequency protocols showing benefit but requiring more high-quality RCTs [148,149,150]. These approaches are best used as adjuncts to evidence-based therapy and medication for moderate-severe disorders, and as primary interventions for mild presentations.

References

  1. Craske, M. G., & Stein, M. B. (2016). Anxiety. The Lancet, 388(10063), 3048–3059.
  2. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). APA Publishing.
  3. Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience, 17(3), 327–335.
  4. Hofmann, S. G., et al. (2012). Cognitive-behavioral therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. Journal of Clinical Psychiatry, 73(4), e21–e22.
  5. Dugas, M. J., & Robichaud, M. (2007). Cognitive-Behavioral Treatment for Generalized Anxiety Disorder. Routledge.
  6. Barlow, D. H. (2002). Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic (2nd ed.). Guilford.
  7. Roy-Byrne, P. P., et al. (2006). Panic disorder. The Lancet, 368(9540), 1023–1032.
  8. Kessler, R. C., et al. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry, 63(4), 415–424.
  9. Craske, M. G., et al. (2010). Panic disorder: A review of DSM-IV panic disorder. Depression and Anxiety, 27(2), 93–112.
  10. Etkin, A., & Wager, T. D. (2007). Functional neuroimaging of anxiety: A meta-analysis. American Journal of Psychiatry, 164(10), 1476–1488.
  11. Shin, L. M., & Liberzon, I. (2010). The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology, 35(1), 169–191.
  12. Stein, M. B., et al. (2017). Generalized anxiety disorder. New England Journal of Medicine, 373(21), 2059–2068.
  13. Hettema, J. M., et al. (2001). A review and meta-analysis of the genetic epidemiology of anxiety disorders. American Journal of Psychiatry, 158(10), 1568–1578.
  14. Smoller, J. W. (2016). The genetics of stress-related disorders. Neuropsychopharmacology, 41(1), 297–319.
  15. Howard, D. M., et al. (2019). Genome-wide meta-analysis of depression identifies 102 independent variants. Nature Neuroscience, 22(3), 343–352.
  16. Stein, D. J., et al. (2014). Defining anxiety disorders in DSM-5. Depression and Anxiety, 31(6), 472–479.
  17. McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation. Physiological Reviews, 87(3), 873–904.
  18. Lupien, S. J., et al. (2009). Effects of stress throughout the lifespan on brain, behaviour and cognition. Nature Reviews Neuroscience, 10(6), 434–445.
  19. Domschke, K., et al. (2010). Interoceptive sensitivity in anxiety and anxiety disorders: An overview. Clinical Psychology Review, 30(1), 1–11.
  20. Roest, A. M., et al. (2010). Anxiety and risk of incident coronary heart disease. Journal of the American College of Cardiology, 56(1), 38–46.
  21. Ohayon, M. M. (2002). Epidemiology of insomnia. Sleep Medicine Reviews, 6(2), 97–111.
  22. Paulus, M. P., & Stein, M. B. (2010). Interoception in anxiety and depression. Brain Structure and Function, 214(5–6), 451–463.
  23. Brown, R. P., & Gerbarg, P. L. (2005). Sudarshan Kriya yogic breathing in the treatment of stress, anxiety, and depression. Journal of Alternative and Complementary Medicine, 11(1), 189–201.
  24. Najavits, L. M. (2002). Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. Guilford.
  25. Foster, G. E., & Sheel, A. W. (2005). The human diving response, its function, and its control. Scandinavian Journal of Medicine & Science in Sports, 15(1), 3–12.
  26. Eifert, G. H., & Heffner, M. (2003). The effects of acceptance versus control contexts on avoidance of panic-related symptoms. Journal of Behavior Therapy and Experimental Psychiatry, 34(3), 293–312.
  27. Bandelow, B., et al. (2017). Efficacy of treatments for anxiety disorders: A meta-analysis. International Clinical Psychopharmacology, 30(4), 183–192.
  28. Slee, A., et al. (2019). Pharmacological treatments for generalized anxiety disorder: A systematic review and network meta-analysis. The Lancet, 393(10173), 768–777.
  29. Carpenter, J. K., et al. (2018). Cognitive behavioral therapy for anxiety and related disorders. Depression and Anxiety, 35(6), 502–514.
  30. Cuijpers, P., et al. (2014). Adding psychotherapy to antidepressant medication in depression and anxiety disorders. World Psychiatry, 13(1), 56–67.
  31. Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. The Lancet, 391(10128), 1357–1366.
  32. Ferguson, J. M. (2001). SSRI antidepressant medications: Adverse effects and tolerability. Primary Care Companion to the Journal of Clinical Psychiatry, 3(1), 22–27.
  33. Lader, M. (2011). Benzodiazepines revisited—will we ever learn? Addiction, 106(12), 2086–2109.
  34. Generoso, M. B., et al. (2017). Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis. International Clinical Psychopharmacology, 32(1), 49–55.
  35. Olatunji, B. O., et al. (2010). Quality of life in the anxiety disorders: A meta-analytic review. Clinical Psychology Review, 27(5), 572–581.
  1. Batelaan, N. M., et al. (2017). Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder. BMJ, 358, j3927.
  2. Stubbs, B., et al. (2017). An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Research, 249, 102–108.
  3. Hofmann, S. G., et al. (2010). The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. Journal of Consulting and Clinical Psychology, 78(2), 169–183.
  4. Andrews, G., et al. (2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. Journal of Anxiety Disorders, 55, 70–78.
  5. Cramer, H., et al. (2018). Yoga for anxiety: A systematic review and meta-analysis of randomized controlled trials. Depression and Anxiety, 35(9), 830–843.
  6. Walker, M. P. (2009). The role of sleep in cognition and emotion. Annals of the New York Academy of Sciences, 1156(1), 168–197.
  7. Lara, D. R. (2010). Caffeine, mental health, and psychiatric disorders. Journal of Alzheimer’s Disease, 20(s1), S239–S248.
  8. Holt-Lunstad, J., et al. (2010). Social relationships and mortality risk: A meta-analytic review. PLoS Medicine, 7(7), e1000316.
  9. Gordon, B. R., et al. (2017). Association of efficacy of resistance exercise training with depressive symptoms: Meta-analysis. JAMA Psychiatry, 75(6), 566–576.
  10. Kandola, A., et al. (2019). Moving to beat anxiety: Epidemiology and therapeutic issues with physical activity for anxiety. Current Psychiatry Reports, 20(8), 63.
  11. Petruzzello, S. J., et al. (1991). A meta-analysis on the anxiety-reducing effects of acute and chronic exercise. Sports Medicine, 11(3), 143–182.
  12. Bruce, M. S., & Lader, M. (1989). Caffeine abstention in the management of anxiety disorders. Psychological Medicine, 19(1), 211–214.
  13. Boschloo, L., et al. (2012). Alcohol use disorders and the course of depressive and anxiety disorders. British Journal of Psychiatry, 200(6), 476–484.
  14. Taylor, G., et al. (2014). Change in mental health after smoking cessation: Systematic review and meta-analysis. BMJ, 348, g1151.
  15. Lehrer, P. M., & Gevirtz, R. (2014). Heart rate variability biofeedback: How and why does it work? Frontiers in Psychology, 5, 756.
  16. Linehan, M. M. (2014). DBT Skills Training Manual (2nd ed.). Guilford.
  17. Foa, E. B., et al. (2007). Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences. Oxford University Press.
  18. Otte, C., et al. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2, 16065.
  19. Pandya, M., et al. (2012). Where in the brain is depression? Current Psychiatry Reports, 14(6), 634–642.
  20. Sullivan, P. F., et al. (2000). Genetic epidemiology of major depression: Review and meta-analysis. American Journal of Psychiatry, 157(10), 1552–1562.
  21. Belmaker, R. H., & Agam, G. (2008). Major depressive disorder. New England Journal of Medicine, 358(1), 55–68.
  22. Beck, A. T., & Bredemeier, K. (2016). A unified model of depression: Integrating clinical, cognitive, biological, and evolutionary perspectives. Clinical Psychological Science, 4(4), 596–619.
  23. Hammen, C. (2005). Stress and depression. Annual Review of Clinical Psychology, 1, 293–319.
  24. Ng, C. W. M., et al. (2017). Depression in primary care: Assessing suicide risk. Singapore Medical Journal, 58(2), 72–77.
  25. Weissman, M. M., et al. (2006). Offspring of depressed parents: 20 years later. American Journal of Psychiatry, 163(6), 1001–1008.
  26. Caspi, A., et al. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386–389.
  27. Schramm, E., et al. (2020). Review of dysthymia and persistent depressive disorder. The Lancet Psychiatry, 7(9), 801–812.
  28. Rosenthal, N. E., et al. (1984). Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry, 41(1), 72–80.
  29. Golden, R. N., et al. (2005). The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis. American Journal of Psychiatry, 162(4), 656–662.
  30. Trivedi, M. H. (2004). The link between depression and physical symptoms. Primary Care Companion to the Journal of Clinical Psychiatry, 6(suppl 1), 12–16.
  31. Simon, G. E., et al. (1999). An international study of the relation between somatic symptoms and depression. New England Journal of Medicine, 341(18), 1329–1335.
  32. Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22–34.
  33. Klein, D. N., & Black, S. R. (2013). Persistent depressive disorder. Annual Review of Clinical Psychology, 9, 39–60.
  34. Cuijpers, P., et al. (2010). Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clinical Psychology Review, 30(1), 51–62.
  35. Stewart, D. E., & Vigod, S. (2016). Postpartum depression. New England Journal of Medicine, 375(22), 2177–2186.
  1. Paulson, J. F., & Bazemore, S. D. (2010). Prenatal and postpartum depression in fathers and its association with maternal depression: A meta-analysis. JAMA, 303(19), 1961–1969.
  2. Meltzer-Brody, S., et al. (2018). Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet, 392(10152), 1058–1070.
  3. Deligiannidis, K. M., et al. (2023). Effect of zuranolone vs placebo in postpartum depression: A randomized clinical trial. JAMA Psychiatry, 80(7), 696–705.
  4. Kroenke, K., et al. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613.
  5. Patten, S. B., et al. (2017). Major depression as a risk factor for chronic disease incidence: Longitudinal analyses in a general population cohort. General Hospital Psychiatry, 30(5), 407–413.
  6. Parker, G. (2000). Classifying depression: Should paradigms lost be regained? American Journal of Psychiatry, 157(8), 1195–1203.
  7. Malhi, G. S., & Mann, J. J. (2018). Depression. The Lancet, 392(10161), 2299–2312.
  8. Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366.
  9. Cuijpers, P., et al. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92–107.
  10. Bauer, M., et al. (2015). World Federation of Societies of Biological Psychiatry guidelines for biological treatment of unipolar depressive disorders. World Journal of Biological Psychiatry, 16(2), 76–95.
  11. McIntyre, R. S., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383–399.
  12. Posternak, M. A., & Zimmerman, M. (2005). Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry, 66(2), 148–158.
  13. Geddes, J. R., et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. The Lancet, 361(9358), 653–661.
  14. Fava, G. A., et al. (2015). Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychotherapy and Psychosomatics, 84(2), 72–81.
  15. Montejo, A. L., et al. (2019). Frequency of sexual dysfunction in patients treated with desvenlafaxine. Journal of Sexual Medicine, 16(12), 1934–1942.
  16. Hammad, T. A., et al. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332–339.
  17. Cuijpers, P., et al. (2013). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. World Psychiatry, 12(2), 137–148.
  18. Cuijpers, P., et al. (2021). Psychological treatment of depression in primary care: Recent developments. Current Psychiatry Reports, 23(8), 36.
  19. Hollon, S. D., et al. (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417–422.
  20. Karyotaki, E., et al. (2017). Efficacy of self-guided internet-based cognitive behavioral therapy in the treatment of depressive symptoms: A meta-analysis of individual participant data. JAMA Psychiatry, 74(4), 351–359.
  21. Solomon, D. A., et al. (2000). Multiple recurrences of major depressive disorder. American Journal of Psychiatry, 157(2), 229–233.
  22. Kuyken, W., et al. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: An individual patient data meta-analysis from randomized trials. JAMA Psychiatry, 73(6), 565–574.
  23. Paykel, E. S. (2008). Partial remission, residual symptoms, and relapse in depression. Dialogues in Clinical Neuroscience, 10(4), 431–437.
  24. Schuch, F. B., et al. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51.
  25. Lam, R. W., et al. (2016). Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 73(1), 56–63.
  26. Riemann, D., et al. (2020). Sleep, insomnia, and depression. Neuropsychopharmacology, 45(1), 74–89.
  27. Lassale, C., et al. (2019). Healthy dietary indices and risk of depressive outcomes: A systematic review and meta-analysis of observational studies. Molecular Psychiatry, 24(7), 965–986.
  28. Liao, Y., et al. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry, 9(1), 190.
  29. Ekers, D., et al. (2014). Behavioural activation for depression: An update of meta-analysis of effectiveness and sub-group analysis. PLoS One, 9(6), e100100.
  30. Cacioppo, J. T., et al. (2006). Loneliness as a specific risk factor for depressive symptoms. Psychology and Aging, 21(1), 140–151.
  31. Brunoni, A. R., et al. (2017). Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. JAMA Psychiatry, 74(2), 143–152.
  32. UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. The Lancet, 361(9360), 799–808.
  33. Goodwin, G. M., et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637–1648.
  34. Ebner-Priemer, U. W., & Trull, T. J. (2009). Ecological momentary assessment of mood disorders and mood dysregulation. Psychological Assessment, 21(4), 463–475.
  35. Shea, A. K., et al. (2017). The role of estrogen in mood and anxiety. Current Opinion in Endocrinology, Diabetes, and Obesity, 24(3), 223–229.
  36. Grande, I., et al. (2016). Bipolar disorder. The Lancet, 387(10027), 1561–1572.
  37. Renaud, S. M., & Zacchia, C. (2012). Toward a definition of affective instability. Harvard Review of Psychiatry, 20(6), 298–308.
  38. Vieta, E., & Suppes, T. (2008). Bipolar II disorder: Arguments for and against a distinct diagnostic entity. Bipolar Disorders, 10(1, pt 2), 163–178.
  39. Merikangas, K. R., et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry, 68(3), 241–251.
  40. Watson, D. (2005). Rethinking the mood and anxiety disorders: A quantitative hierarchical model for DSM-V. Journal of Abnormal Psychology, 114(4), 522–536.
  1. Yonkers, K. A., et al. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200–1210.
  2. Maki, P. M., et al. (2018). Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations. Menopause, 25(10), 1069–1085.
  3. Bauer, M., et al. (2008). The thyroid–brain interaction in thyroid disorders and mood disorders. Journal of Neuroendocrinology, 20(10), 1101–1114.
  4. Zarrouf, F. A., et al. (2009). Testosterone and depression: Systematic review and meta-analysis. Journal of Psychiatric Practice, 15(4), 289–305.
  5. Baglioni, C., et al. (2011). Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders, 135(1–3), 10–19.
  6. Jacka, F. N., et al. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Medicine, 15(1), 23.
  7. Anglin, R. E. S., et al. (2013). Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. British Journal of Psychiatry, 202(2), 100–107.
  8. Coppen, A., & Bolander-Gouaille, C. (2005). Treatment of depression: Time to consider folic acid and vitamin B12. Journal of Psychopharmacology, 19(1), 59–65.
  9. Beard, J. L., et al. (2005). Maternal iron deficiency anemia affects postpartum emotions and cognition. Journal of Nutrition, 135(2), 267–272.
  10. Sarris, J., et al. (2016). Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. American Journal of Psychiatry, 173(6), 575–587.
  11. Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. The Lancet, 381(9878), 1672–1682.
  12. Yatham, L. N., et al. (2018). CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170.
  13. Kessler, R. C., et al. (2015). Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiology and Psychiatric Sciences, 24(3), 210–226.
  14. Lamers, F., et al. (2011). Comorbidity patterns of anxiety and depressive disorders in a large cohort study. Journal of Clinical Psychiatry, 72(3), 341–348.
  15. Fava, M., et al. (2008). Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. American Journal of Psychiatry, 165(3), 342–351.
  16. Barlow, D. H., et al. (2017). The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared with diagnosis-specific protocols for anxiety disorders. JAMA Psychiatry, 74(9), 875–884.
  17. Hawton, K., et al. (2013). Risk factors for suicide in individuals with depression: A systematic review. Journal of Affective Disorders, 147(1–3), 17–28.
  18. Bostwick, J. M., & Pankratz, V. S. (2000). Affective disorders and suicide risk: A reexamination. American Journal of Psychiatry, 157(12), 1925–1932.
  19. Franklin, J. C., et al. (2017). Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research. Psychological Bulletin, 143(2), 187–232.
  20. World Health Organization. (2014). Preventing Suicide: A Global Imperative. WHO Press.
  21. Stanley, B., & Brown, G. K. (2012). Safety planning intervention: A brief intervention to mitigate suicide risk. Cognitive and Behavioral Practice, 19(2), 256–264.
  22. Spitzer, R. L., et al. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097.
  23. American Psychiatric Association. (2024). What is Psychiatry? APA.
  24. American Psychological Association. (2024). Psychologists, Psychiatrists, and Other Mental Health Professionals. APA.
  25. Salk, R. H., et al. (2017). Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychological Bulletin, 143(8), 783–822.
  26. McLean, C. P., et al. (2011). Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illness. Journal of Psychiatric Research, 45(8), 1027–1035.
  27. Twenge, J. M., et al. (2019). Age, period, and cohort trends in mood disorder indicators and suicide-related outcomes in a nationally representative dataset, 2005–2017. Journal of Abnormal Psychology, 128(3), 185–199.
  28. Alexopoulos, G. S. (2005). Depression in the elderly. The Lancet, 365(9475), 1961–1970.
  29. Conwell, Y., et al. (2011). Suicide in older adults. Psychiatric Clinics of North America, 34(2), 451–468.
  30. Twenge, J. M., et al. (2018). Increases in depressive symptoms, suicide-related outcomes, and suicide rates among U.S. adolescents after 2010 and links to increased new media screen time. Clinical Psychological Science, 6(1), 3–17.
  31. Orben, A., & Przybylski, A. K. (2019). The association between adolescent well-being and digital technology use. Nature Human Behaviour, 3(2), 173–182.
  32. Cacioppo, J. T., & Cacioppo, S. (2018). The growing problem of loneliness. The Lancet, 391(10119), 426.
  33. Holt-Lunstad, J., et al. (2015). Loneliness and social isolation as risk factors for mortality: A meta-analytic review. Perspectives on Psychological Science, 10(2), 227–237.
  34. Hunt, M. G., et al. (2018). No more FOMO: Limiting social media decreases loneliness and depression. Journal of Social and Clinical Psychology, 37(10), 751–768.
  35. Goyal, M., et al. (2014). Meditation programs for psychological stress and well-being: A systematic review and meta-analysis. JAMA Internal Medicine, 174(3), 357–368.
  36. Kuyken, W., et al. (2015). Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): A randomised controlled trial. The Lancet, 386(9988), 63–73.
  37. Tang, Y. Y., et al. (2015). The neuroscience of mindfulness meditation. Nature Reviews Neuroscience, 16(4), 213–225.
  38. Arns, M., et al. (2014). Evaluation of neurofeedback in ADHD: The long and winding road. Biological Psychology, 95, 108–115.
  39. van der Kolk, B. A., et al. (2016). A randomized controlled study of neurofeedback for chronic PTSD. PLoS One, 11(12), e0166752.
  40. Micoulaud-Franchi, J. A., et al. (2021). EEG neurofeedback for anxiety disorders and post-traumatic stress disorders: A blueprint for a promising brain-based therapy. Current Psychiatry Reports, 23(12), 84.

Need personalized support?

Dr. Samuel offers evidence-based counselling, therapy, and neurofeedback for anxiety, depression, mood, and trauma — with a 20-minute free consultation.

Book a free 20-minute consultation →